US8609862 — Use of an adrenal hormone-modifying agent
Method of Use · Assigned to Novartis AG · Expires 2031-01-13 · 5y remaining
What this patent protects
This patent protects a method of treating a disease or disorder with increased stress hormone levels and/or decreased androgen hormone levels by administering a specific compound.
USPTO Abstract
The present invention relates to a method of treating a disease or disorder characterised by increased stress hormone levels and/or decreased androgen hormone levels in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I): wherein n is 1 or 3; R is hydrogen or âC(O)N(R a )(R b ) wherein R a and R b are independently â(C 1 -C 4 )alkyl, or â(C 1 -C 4 )alkyl-(C 5 -C 7 )aryl, wherein each of R a and R b is optionally substituted by â(C 1 -C 4 )alkoxy; R 1 , R 2 , and R 3 , are independently hydrogen, halogen, cyano or â(C 6 -C 10 ) aryl, wherein said â(C 6 -C 10 )aryl is optionally substituted by halogen, with the proviso that no more than one of R 1 , R 2 , and R 3 is hydrogen; and R 4 and R 5 are hydrogen; or a pharmaceutically acceptable salt thereof.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-4177 |
— | osilodrostat-phosphate |
U-4177 |
— | osilodrostat-phosphate |
U-2770 |
— | osilodrostat-phosphate |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.